Authors:
Cohn, DE
Mutch, DG
Herzog, TJ
Rader, JS
Dintzis, SM
Gersell, DJ
Todd, CR
Goodfellow, PJ
Citation: De. Cohn et al., Genotypic and phenotypic progression in endometrial tumorigenesis: Determining when defects in DNA mismatch repair and KRAS2 occur, GENE CHROM, 32(4), 2001, pp. 295-301
Authors:
Herzog, TJ
Kowalski, LD
Liu, H
Arlt, M
Swisher, E
Citation: Tj. Herzog et al., Evaluation of a region on chromosome 1p in ovarian serous carcinoma that is frequently deleted in uterine papillary serous carcinoma, GYNECOL ONC, 82(1), 2001, pp. 139-142
Authors:
Basil, JB
Swisher, EM
Herzog, TJ
Rader, JS
Elbendary, A
Mutch, DG
Goodfellow, PJ
Citation: Jb. Basil et al., Mutational analysis of the PMS2 gene in sporadic endometrial cancers with microsatellite instability (vol 74, pg 395, 1999), GYNECOL ONC, 80(1), 2001, pp. 109-109
Authors:
Pinto, AB
Gopal, M
Herzog, TJ
Pfeifer, JD
Williams, DB
Citation: Ab. Pinto et al., Successful in vitro fertilization pregnancy after conservative management of endometrial cancer, FERT STERIL, 76(4), 2001, pp. 826-829
Authors:
Cohn, DE
Basil, JB
Venegoni, AR
Mutch, DG
Rader, JS
Herzog, TJ
Gersell, DJ
Goodfellow, PJ
Citation: De. Cohn et al., Absence of PTEN repeat tract mutation in endometrial cancers with microsatellite instability, GYNECOL ONC, 79(1), 2000, pp. 101-106
Authors:
Bookman, MA
Blessing, JA
Hanjani, P
Herzog, TJ
Andersen, WA
Citation: Ma. Bookman et al., Topotecan in squamous cell carcinoma of the cervix: A phase II study of the gynecologic oncology group, GYNECOL ONC, 77(3), 2000, pp. 446-449
Authors:
Cohn, DE
Babb, S
Whelan, AJ
Mutch, DG
Herzog, TJ
Rader, JS
Elbendary, A
Goodfellow, PJ
Citation: De. Cohn et al., Atypical clustering of gynecologic malignancies: A family study including molecular analysis of candidate genes, GYNECOL ONC, 77(1), 2000, pp. 18-25
Authors:
Grigsby, PW
Perez, CA
Chao, KSC
Elbendary, A
Herzog, TJ
Rader, JS
Mutch, DG
Citation: Pw. Grigsby et al., Lack of effect of tumor size on the prognosis of carcinoma of the uterine cervix stage Ib and IIa treated with preoperative irradiation and surgery, INT J RAD O, 45(3), 1999, pp. 645-651
Authors:
Markman, M
Blessing, JA
DeGeest, K
Morgan, M
Look, KY
Herzog, TJ
Rose, PG
Citation: M. Markman et al., Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A gynecologic oncology group trial, GYNECOL ONC, 75(3), 1999, pp. 444-446
Authors:
Basil, JB
Swisher, EM
Herzog, TJ
Rader, JS
Elbendary, A
Mutch, DG
Goodfellow, PJ
Citation: Jb. Basil et al., Mutational analysis of the PMS2 gene in sporadic endometrial cancers with microsatellite instability, GYNECOL ONC, 74(3), 1999, pp. 395-399
Citation: Er. Kost et al., Interferon-gamma and tumor necrosis factor-alpha induce synergistic cytolytic effects in ovarian cancer cell lines - Roles of the TR60 and TR80 tumornecrosis factor receptors, GYNECOL ONC, 72(3), 1999, pp. 392-401
Authors:
Swisher, EM
Peiffer-Schneider, S
Mutch, DG
Herzog, TJ
Rader, JS
Elbendary, A
Goodfellow, PJ
Citation: Em. Swisher et al., Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability, CANCER, 85(1), 1999, pp. 119-126